
Our center is a government-approved cancer cell therapy institution, authorized by the Ministry of Health and Welfare. To date, we have successfully treated more than 195 patients. With a dedicated medical team, we design personalized treatment plans to help patients enhance their confidence and achieve better therapeutic outcomes. Our cancer control rate reaches an average of 77%, with minimal side effects.
Our center is approved to provide five types of cell therapy—DC, DC (tumor-free), CIK, DC-CIK, and NK—and we focus on 15 types of hard-to-treat cancers, achieving a disease control rate of up to 77%. This demonstrates an innovative model of regenerative medicine that combines both safety and effectiveness.

Chung Shan Medical University Hospital
Tsao Chang-Yao, M.D., P.h.
Professor of Internal Medicine
Director of the Center for Immune Cell Therapy
Director of the Subject Protection Center
Work Experience
• Vice President of Chung Shan Medical University (2010–2020)
• Vice Superintendent of Chung Shan Medical University Hospital
• Deputy Superintendent of Tzu Chi Hospital, Taipei Branch
• Director and Professor of Pulmonary Unit, Chang Gung Memorial Hospital, Linkou
Academic Background
• Doctorate in Clinical Medicine, Chang Gung Medical University
• Research Fellow, Harvard Medical School, Massachusetts General Hospital
Specialties
Lung cancer, immunotherapy, asthma, cough, chest pain, shortness of breath, pneumonia, and obstructive pulmonary disease.

Hello, and welcome to the Chung Shan Medical University Hospital Immunotherapy Center group!
Nurse Tseng and Nurse Hsu will assist you as soon as possible.
📞 Service phone: 04-24739595 ext. 21713 or 21715
🕘 Consultation hours: Monday to Friday, 9:00 AM – 5:00 PM
Please send a sticker to let us know you’ve joined our group! 😊
Kind reminder:
This group is a one-on-one chat, so your messages will not be visible to other members.
If you prefer not to receive notifications, you can tap the menu icon in the upper right corner of the screen and turn off “Notifications.”
